Invesco Ltd. Caribou Biosciences, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 66,086 shares of CRBU stock, worth $106,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,086

Previous 67,200 1.66%

Holding current value

$106,398

Previous $110,000 16.36%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.56 - $2.73 $1,737 - $3,041	-1,114 Reduced 1.66%	66,086 $128,000
Q2 2024 Aug 13, 2024	SELL	$1.62 - $5.05 $4,960 - $15,463	-3,062 Reduced 4.36%	67,200 $110,000
Q1 2024 May 14, 2024	SELL	$4.82 - $8.26 $32,616 - $55,895	-6,767 Reduced 8.79%	70,262 $361,000
Q4 2023 Feb 12, 2024	BUY	$3.58 - $6.25 $31,020 - $54,156	8,665 Added 12.67%	77,029 $441,000
Q3 2023 Nov 13, 2023	BUY	$4.08 - $8.14 $9,865 - $19,682	2,418 Added 3.67%	68,364 $326,000
Q2 2023 Aug 11, 2023	SELL	$4.04 - $5.47 $14,208 - $19,237	-3,517 Reduced 5.06%	65,946 $280,000
Q1 2023 May 12, 2023	BUY	$4.3 - $7.78 $206,064 - $372,833	47,922 Added 222.47%	69,463 $368,000
Q4 2022 Feb 13, 2023	SELL	$5.57 - $11.01 $1.63 Million - $3.23 Million	-293,511 Reduced 93.16%	21,541 $135,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $1.58 Million - $3.79 Million	296,643 Added 1611.4%	315,052 $3.32 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $32,109 - $61,323	6,296 Added 51.98%	18,409 $100,000
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $101,991 - $185,571	12,113 New	12,113 $110,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $98M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account